Signal integration in the mTOR pathway plays a vital role in cell fate decision making in cancer cells.
Introduction
Cancer cells have dysregulated networks of signaling pathways which provide them with the capability to develop specific characteristics defined as hallmarks of cancer [1] [2] [3] . Considering the functions of these signaling pathways in time and space using mathematical models and systemslevel approaches offer novel insights for the discovery and optimization of therapeutic regimens for cancer [4] [5] [6] . The ability of cancer cells to develop resistance and escape from effects of treatment modalities comes from the complex information processing system which surfs the stress signals within and among the cancer cells. Systems-level analysis of high-throughput omics data of signal propagation and decision-making system in cancer cells can discover new precision and personalized treatments. Understanding the dynamics of functional modules and signal integrators in malignant cells is an essential part of these efforts [3, 7, 8] .
Mammalian target of rapamycin (mTOR) also known as mechanistic target of rapamycin is an important signal integrator in the cells which controls many functions such as cell survival, cell death and aging [9] [10] [11] . mTOR is a serine-threonine protein kinase which functions at the intersection of the networks of cellular homeostasis control. mTOR receives signals from different functional modules in cells such as stress sensors, metabolic imbalance sensors, cell cycle, and cell size control system and within its complex interactions with other compartments contribute to cell fate decision in terms of cell death and survival [1, [10] [11] [12] [13] . Role of mTOR as a signal integrator not only is defined by the signaling networks in which it is involved but also by the temporal processes of signal integration and transduction [14] [15] [16] [17] .
Organization of the mTOR signaling pathway has a modular design in which two main complexes, which are mTOR complex 1 (mTORC1) and mTOR Complex 2 (mTORC2), are the basic elements.
In terms of responses of mTOR to different signals, mTORC1 controls activation of synthesis of macromolecules such as proteins and lipids, cell growth and cell cycle progression, metabolic reprogramming and suppression of autophagy. Basically, under physiological condition, when there is no cellular stress, and cell metabolic state is at homeostasis in the presence of growth factors, sufficient nutrients (particularly amino acids), and enough oxygen, mTORC1 transduces a signal to increase production of cellular building blocks, as well as the cell growth, while suppressing autophagy which degrades the cell's own materials and organelles. Inhibition of mTOR, which happens under stress condition and drug treatment, induces opposite responses to keep the cell survival and avoid cell death in time of limited nutrients and increased stress [1, 10, 11, 18, 19] . (Figure 1) mTOC1 is a protein complex composed of mTOR, DEPTOR, PRAS40, mLST8, and Raptor [20, 21] ; while mTORC2 consists of another set of proteins including mTOR, mSin, DEPTOR, Rictor, Protor1/2 and mLST8 [20, 22] . mTORC2 contributes to metabolic reprogramming, cytoskeletal organization and cell survival through signal transduction when it receives the signal from growth factors [10, 11, 20] . To clarify, mTORC2 phosphorylates Akt (Protein Kinase B) and activates the survival responses downstream of Akt [10, 11, 14, 18] .
Rapamycin (sirolimus) is a macrolide with immunosuppressive, anti-neoplastic and anti-aging effects which is known as an mTOR inhibitor [20, [23] [24] [25] . Rapamycin is used as an mTOR inhibitor for different clinical conditions such as cancer and organ transplantation [26, 27] . Upon entering a cell, rapamycin binds to 12-kDa FK506-binding protein (FKBP12), and then this complex suppresses the kinase activity of mTORC1 [24] . Although it is believed that rapamycin imposes its inhibition on mTOR via mTORC1 complex [11, 28] , but there is evidence showing a more complex mechanism of action which is determined based on the temporal properties of rapamycin treatment [24, [29] [30] [31] . For example, short-term treatment with rapamycin renders cells more sensitive to insulin via mTORC1 while long-term exposure increases the insulin resistance which happens via affecting mTORC2 [31] .
In fact, prolonged rapamycin treatment can inhibit mTORC2, leading to inhibition of Akt/PKB signal [24] . The topology of molecular interactions in the mTOR pathway cannot provide enough insights on how differential responses can occur with different temporal dose schedules of rapamycin treatment. The dynamics of this interaction network can shed light on paradoxical responses in terms of mTORC1 and mTORC2 activities [32, 33] . To address this question, we used a dynamical model of interactions of the mTOR complexes. There are some facts on time-scales of mTOC1 and mTOC2 behaviors: inhibition of mTORC1 happens in the first 30 minutes of exposure while HeLa cells, for instance, lose the mTORC2 only if the rapamycin exposure takes up to at least 24 hours [24] .
We hypothesize that it is based on Le Chatelier's principle [34] that rapamycin can inhibit mTORC2.
Rapamycin binds directly to mTORC1 and dissociates Raptor from mTOR, while it is unable to bind to pre-formed mTORC2. Sequestration of mTOR by rapamycin eventually blocks the formation of new mTORC2, and that is why the inhibition of mTORC2 takes much time to happen. (Figure 2) Another possible mechanism can be the contribution of Phosphatidic Acid (PA) which is required for the formation of mTORC1 and mTORC2. PA stabilizes mTORC2 more strongly compared to mTORC1 while rapamycin reduces this stability [35, 36] . To analyze the dynamics of rapamycin action upon mTOR complexes and evaluate the validity of this hypothesis, we present a mathematical model of interactions among rapamycin, mTOR, mTORC1, and mTORC2using using Ordinary Differential Equations (ODEs).
Methods
The Model: A model of cellular responses to rapamycin using mTOR signaling was developed by translating the interaction diagram in Figure 2 into a set of ODEs. Since all the reactions in this model are concentration-dependent, they follow the law of mass action and the first order kinetic law. We also assume that we are treating a population of cells that all of them are resistant to rapamycininduced apoptosis; thus, no cell death occurs after treatment. When administered for a long time, we then assume that when cells divide, all daughter cells carry the same amount of species as the mother cells. Therefore, simulation for one cell represents the result of the average of the cell population, regardless of the number of cell divisions occurred. The list of species and parameters and the final values assigned to them are provided in Tables 1,2 and calculated the dissociation rate constant to be 5 min -1 (= 0.083 S -1 ) [38] . (Supplementary Table   S2 )
Association and dissociation rate constants of rapamycin and mTOR were extracted from Banaszynski et al. [39] , which reported the association and dissociation rate constants of formation of trimeric FKBP12-rapamycin-mTOR complex as 1.92*10 6 M -1 .S -1 and 2.2*10 -2 S -1 , respectively.
Hereby, for the simplicity of our model, we ignored the binding of rapamycin with FKBP12 and assumed the cytosolic rapamycin is FKBP12-Rapamycin (Supplementary Table S2 ).
Similarly, the average quantity of mTOR, Raptor, and Rictor in a cell was extracted from Geiger et al. [40] which measured total proteome of eleven cell lines. Furthermore, we assumed the volume of a cell to be 5*10 -12 liter and calculated concentrations of mTOR, Raptor, and Rictor based on Geiger et al. [40] . (Supplementary Table S2 )
We could not find any studies that even could remotely estimate mTOR-Rictor binding rate constants.
Hence, initially, we assumed the association-dissociation rate constants of mTOR and Rictor interaction (kC2f and kC2d) to be equal to that of mTOR and Raptor interaction (kC1f and kC1d). Then we scanned every parameter space within a range logarithmically spaced from -3logs to +3logs using seven steps to see how changing each parameter affects the outputs. Additionally, we scanned the parameter space of the macro-constants of rapamycin (Kabs and Kel) within a range logarithmically spaced from -2logs to +2logs using three steps.
Moreover, we chose the values for synthesis and degradation rate constants of mTOR, Raptor, and
Rictor in a way to have the least effect on the main question, also, in a way to have an almost similar amount of these species, in total, in the beginning, and after reaching the equilibrium.
Dose schedules for rapamycin:
Four dose-interval schedules were selected to be used in this model:
Ⅰ-A low-dose and short-interval schedule (8.0*10 -20 mole/Day).
Ⅱ-A high-dose and short-interval schedule (5.6*10 -19 mole/Day).
Ⅲ-A high-dose and long-interval schedule (5.6*10 -19 mole/Week).
Ⅳ-A very high-dose and long-interval schedule (2.24*10 -18 mole/Week).
Considering the maximum whole-blood concentration of rapamycin for transplant patients equal to ~15 ng/ml [41] and the molecular weight of rapamycin equal to ~914 g/mole [42] , if we assume the cytosolic concentration of rapamycin is equal to that of the whole-blood, we can calculate that ~8.0 Moreover, we can administer 5.6 x 10 -19 moles of rapamycin on a daily basis to have regimen Ⅱ.
Finally, we can multiply the third regimen by 4 to have 2.24 x 10 -18 mole/Week as a very high dose with a weekly interval (regimen Ⅳ). Besides this, we scanned a ± 20% area (linearly divided into five steps) for every treatment we defined in the simulations. The dose specifications in SimBiology are listed in Table 4 .
We measured minimum, maximum and average residual active percentage of mTORC1 (mTORC1%min, mTORC1%max, and mTORC1%avg.) and mTORC2 (mTORC2%min, mTORC2%max, and mTORC2%avg.) in each schedule as a representative of their activity.
Results
The mathematical model based on the interaction diagram of Figure 2 , can generate temporal changes in the concentration of different components in the model and reveal the dynamics of the mode of action of rapamycin using different doses of rapamycin within different treatment schedules. The temporal changes of rapamycin concentration in regimens Ⅰ to Ⅳ are shown in Figure 3 . The corresponding temporal concentration of mTORC1 and mTORC2 is presented in Figure 4 , and the corresponding data can be found in Table 5 as the minimum, average and maximum residual active percentage of the two complexes, for the exact 100% dose of each schedule. In (Table 5) .
Supplementary
Furthermore, the distinguishable feature of the regimen Ⅱ is that not only it has a very high Cmax concentration but also possesses a much higher pre-dose concentration of rapamycin, in contrast to every other schedule (Figure 3) . Also, both mTOR complexes are almost strongly inhibited by rapamycin in this schedule (regimen Ⅱ): mTORC1%avg. equals 18.28% and mTORC2%avg. is 51.03%
( Figure 4 and Table 5 ). In an almost similar fashion, the regimen Ⅳ has a very high Cmax and a high enough Cmin (higher than Cmin of the regimen Ⅰ and Ⅲ, but not regimen Ⅱ) that keeps mTORC1 inhibited, even in the pre-dose time (61.30% residual activity) while mTORC2 activity comes back to almost normal (84.14% residual activity).
Altering both Kabs and Kel in two orders of magnitude (± 2logs) changes the temporal concentration of rapamycin, mTORC1, and mTORC2. However, mTORC1 is still inhibited much more profoundly compared with mTORC2. (Figure 5 and Supplementary Table S4) The mTORC1%avg. and mTORC2%avg. are affected by changing the value of formation and dissociation rate constants of these two complexes (kc1f, kc1d, kc2f, and kc2d) in an area of ± 3logs
( Figure S1 and Table 6 ). Note that if the C2% > C1% but KD1< KD2, it means that while mTORC2
is weaker than mTORC1, mTORC2 is less affected by rapamycin.
In figure S1 And Supplementary Table S5 , it is shown that how mTORC1%avg. and mTORC2%avg.
are affected by scanning ki1f, ki1r, ki2f, ki2r, ki3f and ki3r in an area of ± 3logs. C2% > C1% is true for all cases, which means none of these ± 3logs-scans made mTORC2 being affected more than mTORC1.
Discussion
The dynamics portrayed by mathematical model shows that even with neglecting the role of PA and only by considering the Le Chatelier's principle [34, 43] , mTORC2 is mechanistically inhibited only after prolonged rapamycin exposure in cells. This model magnifies the importance of in silico dynamical models to understand the mechanism of signal transduction considering drug treatments.
By evaluating the interaction network statically controlling mTOR complexes, rapamycin cannot directly inhibit mTORC2. by observing the dynamics of this network, if the concentration of rapamycin persistently remains high enough, sequestration of the free mTOR prompts the equilibrium of mTORC2 formation (mTOR + Rictor ⇌ mTORC2) to choose the reverse path, based on Le
Chatelier's principle, and consumes the pre-formed mTORC2. Based on comprehending our results in conjunction with the literature, PA might only increase the confidence of this mechanism. It means that the amount of PA in a cell only determines how long it takes for the mTORC2 in that specific cell to be affected by rapamycin. According to our mathematical model, mTORC2 inhibition can be avoided by increasing the interval of rapamycin to reduce the trough concentration below the minimum effective dose.
One of the paradoxes regarding the role of mTOR signaling in aging is that rapamycin increases female but not male lifespan in mice [44, 45] . However, Leontieva et al. [46] indicated that "weekly" administration of rapamycin could extend the male lifespan while avoiding the detrimental side effects that other studies described. Regarding metabolic effects of rapamycin, Arriola Apelo et al. [47] clarified that an intermittent administration of rapamycin (every five days) reduces its side effects on glucose metabolism, insulin sensitivity, and immune system. They showed that the reason for this phenomenon is that mTORC2 is not affected in this regimen [47] . They also reported the efficacy of intermittent rapamycin administration in promoting the female lifespan in mice [48] . Again, our model demonstrates the mechanism by which this intermittent administration (long interval) helps in avoiding mTORC2 inhibition.
It has been shown that selective or targeted mTORC2 inhibition causes reduced cell proliferation, tumor size, and angiogenesis in several types of cancers including colon cancer, breast cancer and multiple myeloma [49] [50] [51] [52] [53] . Differential effects of dose-interval schedules of rapamycin (or rapalogs) on colon cancer have also been investigated. Guba et al. [54, 55] employed three schedules of rapamycin with equal cumulative doses: Ⅰ) Once daily (QD); Ⅱ) Once every three days (Q3D); and Ⅲ) Continuous IV infusion. Interestingly, they observed that while the IV infusion produced the least plasma concentration, it was the most effective one against colon cancer xenografts. Furthermore, the Q3D dose showed the least efficacy regarding the inhibition of tumor growth. It can be reasonably deduced from this study that prolonged duration of exposure to sufficiently high concentrations of rapamycin is necessary for its mTORC2-related effects. Considering results of Guba et al. [54, 55] , comparing regimen I and III of our model (which have equal cumulative doses) clearly shows why the Q3D schedule cannot inhibit tumor growth: if the cumulative dose is constant and the interval is prolonged, while the Cmax gets higher, the Cmin (trough concentration) drops drastically, and the mTORC1 and mTORC2 activity comes back to their approximate normal state long before the next dose is administered. Now, not only the mTORC2 signal is not interrupted, but also the negative feedback of mTORC1 on the input signal of growth factors is removed; thus, the tumor cells have the chance to grow and divide again.
It is shown that inhibition of mTORC1 leads to improved immune profiles in the elderly while inhibition of mTORC2 is responsible for adverse events [56] . Mannick et al. [56] have mentioned that mTORC1 inhibition is enough to strengthen the immune system, amplifying the response to influenza vaccine and decreasing the overall rate of infection in elderly subjects [56] . Mannick et al.
[57] administered three dose-interval schedules of everolimus, which is a rapamycin-like mTOR However, the 20 mg/Week regimen showed more side effects, likely due to almost full inhibition of mTORC1 and (at least) partial inhibition of mTORC2 [57] . Here in our model, comparing regimens Ⅲ and Ⅳ, the activity of both complexes come back to an almost equal amount at the pre-dose area (mTORC1%max = 72.30% vs. 61.30% and mTORC2%max = 89.71% vs. 84.14% for regimen Ⅲ vs.
Ⅳ, respectively). However, looking at the average residual activity in these two regimens, both mTOR complexes are much more prominently inhibited in regimen Ⅳ (mTORC1%avg.= 58.01% vs.
33.37% and mTORC2%avg.= 82.02% vs. 58.43% for regimen Ⅲ vs. Ⅳ, respectively). Hence, our model confirms the findings of Mannick et al.
[57]: A very high dose and weekly-administered rapamycin inhibits mTORC2 to a greater extent, leading to extra side effects.
Regarding the association and dissociation rate constants of mTORC2 (kc2f and kc2d), and also KD1 and KD2, it is difficult to conclude which values are the closest to the real values. Toschi et al. [58] claim that KD1 must be higher than KD2 (meaning, Rictor binds to mTOR more tightly than Raptor does) to see rapamycin inhibits mTORC1 more than mTORC2, and this is made possible by the higher affinity of PA for mTORC2 compared to mTORC1. Simulations of our mathematical model show that even with hypothetical values for mTORC2 rate constants, in some cases, we observe that KD2 is less than KD1 (which means Raptor has a higher affinity towards mTOR compared to Rictor), yet mTORC1 is still inhibited more than mTORC2. Although we need an accurate experimental design to find out mTORC2 formation and dissociation rate constants, these counterexamples undermine PA as a critical regulator of mTOR complexes, while keeps the possibility that PA might be one of many players that ensures the stability of mTORC2.
Although future quantitative experiments can improve our model, it is a useful framework to understand the dynamics of signal integration and transduction by mTOR. While it is claimed that PA helps with stabilizing the mTORC2 more than mTORC1, our model reveals that the actual mechanism by which rapamycin affects mTORC2 integrity is through Le Chatelier's principle. This finding has translational implications, and it will be a useful approach to design rapalogs that target one of the two mTOR complexes more selectively only by modifying their affinity towards either mTORC1 or the free mTOR.
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